Feprazone

Feprazone (DA2370; Prenazone), an analogue of Phenylbutazone (HY-B0230), is a nonsteroidal anti-inflammatory agent with analgesic and antipyretic activities. Feprazone acts by inhibiting the activity of cyclooxygenase (COX) -2. Feprazone ameliorates free fatty acid (FFA) -induced oxidative stress by reducing the production of mitochondrial reactive oxygen species (ROS) . Feprazone can decrease the expression of MMP-2 and MMP-9. Besides, Feprazone can suppress adipogenesis and increase lipolysis in differentiating 3 T3-L1 cells. Feprazone also can be used to research atherosclerosis and obesity[1][2][3].

Product Specifications

CAS Number

[30748-29-9]

Product Name Alternative

DA2370; Prenazone; Zepelin

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

COX; MMP; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/feprazone.html

Purity

99.88

Solubility

DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3)C1C/C=C(C)\C

Molecular Formula

C20H20N2O2

Molecular Weight

320.39

Precautions

H315, H319, H335

References & Citations

[1]Song M, et al. Feprazone Prevents Free Fatty Acid (FFA) -Induced Endothelial Inflammation by Mitigating the Activation of the TLR4/MyD88/NF-κB Pathway. ACS Omega. 2021 Feb 9;6 (7) :4850-4856.|[2]Fletcher MR, et al. Feprazone, a new anti-inflammatory agent. Studies of potency and gastrointestinal tolerance. Ann Rheum Dis. 1975 Apr;34 (2) :190-4.|[3]Che L, et al. Feprazone Displays Antiadipogenesis and Antiobesity Capacities in in Vitro 3 T3-L1 Cells and in Vivo Mice. ACS Omega. 2021 Mar 7;6 (10) :6674-6680.